Loading
A phase 3 trial of Durvalumab, Methotrexate, Vinblastine, Doxorubicin, Cisplatin and Gemcitabine in bladder & urothelial cancer, run by AstraZeneca, now recruiting.
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) is a phase 3 interventional study registered as NCT06960577 by AstraZeneca, with 150 participants planned, started 2025-05-15 and due to reach its primary completion in 2028-10-31. Interventions recorded: Durvalumab, Methotrexate, Vinblastine, Doxorubicin, Cisplatin and Gemcitabine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Durvalumab, Gemcitabine, AstraZeneca and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Durvalumab, Gemcitabine, AstraZeneca and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Platinum agents and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Platinum agents and the tag pipeline.
Shares Durvalumab, Gemcitabine, AstraZeneca, Platinum agents and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Durvalumab, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.
Shares Durvalumab, Gemcitabine, Platinum agents, Cisplatin and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/